A clinical study called SEAS has shown a link between Vytorin and cancer. Vytorin is a cholesterol-lowering drug, that is prescribed to millions of people. The SEAS study was done to determine whether Vytorin could help prevent further heart problems in people with heart-valve disease. The results of the study did not demonstrate that benefit. Instead, the lead investigator of the study found a link to increased cancer risk. Vytorin combines Zetia with a statin in a single pill. Vytorin and Zetia, sold by Merck and Schering-Plough, are among the top-selling drugs around the world. The cholesterol-lowering power of Vytorin prompted its approval in 2004. However, some physicians are expressing caution about the drug in light of the SEAS findings, despite the absence of a cancer link in two other Vytorin studies. The doctors who express concern say that more trial evidence is needed to definitively establish Vytorin’s safety. There are currently two ongoing large-scale clinical trials comparing Vytorin to simvastatin or Zocor. Some physicians are urging that only patients who can’t sufficiently lower their cholesterol with a statin, should use Vytorin.
The Legal Examiner and our Affiliate Network strive to be the place you look to for news, context, and more, wherever your life intersects with the law.
Comments for this article are closed.